IFNGR1 Knockout HT29 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the IFNGR1 gene. This loss-of-function model eliminates the ligand-binding subunit of the interferon gamma receptor, enabling researchers to dissect the role of interferon gamma signaling in a human colorectal adenocarcinoma background. The polyclonal format preserves genetic diversity while abrogating IFNGR1 expression across the cell pool, making it suitable for bulk functional genomic studies without the limitations of clonal selection.
HT29 cells serve as a well-characterized host line derived from a primary colon adenocarcinoma. Exhibiting epithelial morphology, they are extensively utilized in cancer research, drug transport assays, and intestinal barrier studies. Their reproducible growth characteristics and relevance to colorectal cancer biology establish a robust platform for investigating tumor-intrinsic immune signaling. The integration of an IFNGR1 knockout into this model generates a powerful tool for examining how loss of interferon gamma responsiveness impacts epithelial tumor cell behavior.
The IFNGR1 protein functions as the high-affinity receptor chain for interferon gamma (IFNG). Upon ligand binding, it heterodimerizes with IFNGR2, which recruits and activates the tyrosine kinases JAK1 and JAK2. This initiation event triggers phosphorylation of STAT1, followed by its nuclear translocation and transcriptional induction of interferon-stimulated genes including IRF1 and CXCL10. The JAK-STAT cascade thereby translates extracellular cytokine signals into a broad innate immune response. In the knockout model, disruption of IFNGR1 incapacitates the receptor complex, preventing downstream JAK1/JAK2 activation and subsequent STAT1-driven gene expression.
Within the HT29 colorectal cancer context, abolishing IFNGR1 eliminates the cell’s ability to respond to interferon gamma, a cytokine with dual tumor-suppressive and tumor-promoting properties. This knockout enables investigation of interferon gamma’s effects on proliferation, apoptosis, antigen presentation, and immune evasion in an epithelial tumor setting. It is particularly valuable for studying the interplay between tumor cells and the immune microenvironment, as well as for validating targets within the JAK-STAT pathway relevant to colorectal cancer. The model also allows assessment of how cancer cells overcome interferon gamma-mediated control.
Applications span interferon gamma signaling studies, immune checkpoint research, inflammation and infection models, and drug screening for JAK-STAT inhibitors. Representative assays include western blotting, RT-qPCR, immunofluorescence, flow cytometry, RNA-seq, STAT1 phosphorylation analysis, drug sensitivity tests, and cytokine response assays. These cells support both mechanistic investigations and translational research aimed at identifying therapeutic strategies that modulate the interferon gamma pathway. For further details, please contact Ascent Research.
